---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-141371"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:27:00.206055+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio Q1 2023: R&D spend $12.4M; CABA-201 IND cleared, Fast Track granted

## Summary
- R&D expenses $12.4M (Q1 2023) vs $9.2M (Q1 2022); G&A $4.5M vs $3.8M.
- Cash and equivalents $93.8M as of March 31, 2023; runway into Q1 2025.
- FDA cleared IND for CABA-201 Phase 1/2 trial in lupus nephritis and SLE; Fast Track Designation granted.
- Trial to enroll 6 LN and 6 SLE patients at 1.0x10^6 cells/kg; three-month efficacy data expected H1 2024.
- Preclinical and updated DSG3-CAART data to be presented at ASGCT 26th Annual Meeting May 16-20.

## SEC filing metadata
- accession: 0001193125-23-141371
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312523141371/0001193125-23-141371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312523141371/d669630d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-141371
- JSON: https://secwatch.observer/filing/0001193125-23-141371.json
- Plain text: https://secwatch.observer/filing/0001193125-23-141371.txt

## Key facts
- Earnings Releases
  Cabaletta Bio, Inc. reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 11, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759138/000119312523141371/0001193125-23-141371-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.